Compare Stocks: CLDI, APRE, MTVA, and TOVX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$0.66 +2.5%	$0.71	$0.55 ▼ $1.79	$7.98M	1.52	56,846 shs	24,183 shs
CLDI Calidi Biotherapeutics	$1.64 +0.6%	$2.19	$1.48 ▼ $96.95	$1.97M	1.33	480,765 shs	231,099 shs
MTVA MetaVia	$1.42 -0.7%	$1.67	$0.97 ▼ $19.03	$7.39M	0.95	110,122 shs	50,622 shs
TOVX Theriva Biologics	$0.23 -0.4%	$0.24	$0.16 ▼ $0.86	$7.79M	1.11	502,995 shs	411,008 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-0.92%	+7.80%	-13.52%	-28.41%	-62.10%
CLDI Calidi Biotherapeutics	+0.62%	-2.98%	-27.70%	-46.38%	-97.97%
MTVA MetaVia	-4.03%	-3.38%	-19.66%	+47.42%	-79.36%
TOVX Theriva Biologics	+4.62%	+3.73%	-4.51%	-28.24%	-37.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$0.66 +2.5%	$0.71	$0.55 ▼ $1.79	$7.98M	1.52	56,846 shs	24,183 shs
CLDI Calidi Biotherapeutics	$1.64 +0.6%	$2.19	$1.48 ▼ $96.95	$1.97M	1.33	480,765 shs	231,099 shs
MTVA MetaVia	$1.42 -0.7%	$1.67	$0.97 ▼ $19.03	$7.39M	0.95	110,122 shs	50,622 shs
TOVX Theriva Biologics	$0.23 -0.4%	$0.24	$0.16 ▼ $0.86	$7.79M	1.11	502,995 shs	411,008 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-0.92%	+7.80%	-13.52%	-28.41%	-62.10%
CLDI Calidi Biotherapeutics	+0.62%	-2.98%	-27.70%	-46.38%	-97.97%
MTVA MetaVia	-4.03%	-3.38%	-19.66%	+47.42%	-79.36%
TOVX Theriva Biologics	+4.62%	+3.73%	-4.51%	-28.24%	-37.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	2.40	Hold	$4.07	516.07% Upside
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
MTVA MetaVia	2.00	Hold	$20.00	1,308.45% Upside
TOVX Theriva Biologics	3.00	Buy	$1.00	334.78% Upside

Current Analyst Ratings Breakdown

Latest CLDI, APRE, MTVA, and TOVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	MTVA MetaVia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	APRE Aprea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/18/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
5/14/2026	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $6.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$290K	28.18	N/A	N/A	$1.52 per share	0.43
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	$1.32 per share	N/A
TOVX Theriva Biologics	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.60M	-$1.54	N/A	N/A	N/A	-4,405.59%	-61.03%	-50.24%	8/11/2026 (Estimated)
CLDI Calidi Biotherapeutics	-$19.91M	N/A	N/A	N/A	N/A	N/A	-424.58%	-182.38%	N/A
MTVA MetaVia	-$12.97M	-$5.19	N/A	N/A	N/A	N/A	-209.67%	-107.91%	N/A
TOVX Theriva Biologics	-$23.74M	-$33.06	N/A	N/A	N/A	N/A	-178.29%	-59.96%	N/A

Latest CLDI, APRE, MTVA, and TOVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	APRE Aprea Therapeutics	-$0.1775	N/A	N/A	N/A	$0.25 million	N/A
8/11/2026	Q2 2026	TOVX Theriva Biologics	N/A	-$0.07	N/A	-$0.07	N/A	N/A
8/6/2026	Q2 2026	MTVA MetaVia	-$0.82	-$0.90	-$0.08	-$0.90	N/A	N/A
5/14/2026	Q1 2026	CLDI Calidi Biotherapeutics	N/A	-$6.88	N/A	-$0.43	N/A	N/A
5/14/2026	Q1 2026	MTVA MetaVia	-$0.76	-$0.79	-$0.03	-$0.79	N/A	N/A
5/13/2026	Q1 2026	APRE Aprea Therapeutics	-$0.23	-$0.22	+$0.01	-$0.22	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
TOVX Theriva Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	8.92	8.92
CLDI Calidi Biotherapeutics	0.15	1.92	1.92
MTVA MetaVia	N/A	2.06	2.06
TOVX Theriva Biologics	0.11	1.63	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
CLDI Calidi Biotherapeutics	12.53%
MTVA MetaVia	1.37%
TOVX Theriva Biologics	6.17%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	10.49%
CLDI Calidi Biotherapeutics	4.30%
MTVA MetaVia	0.60%
TOVX Theriva Biologics	1.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	12.38 million	11.08 million	No Data
CLDI Calidi Biotherapeutics	38	1.21 million	1.16 million	N/A
MTVA MetaVia	8	5.16 million	5.13 million	N/A
TOVX Theriva Biologics	20	33.74 million	33.40 million	Not Optionable

CLDI, APRE, MTVA, and TOVX Headlines

Recent News About These Companies

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2026

August 11 at 4:00 PM | globenewswire.com

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line ...

August 6, 2026 | finance.yahoo.com

Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 1.4% - Here's Why

August 6, 2026 | americanbankingnews.com

Theriva Biologics Expands Stock Incentive and Governance Plans

August 4, 2026 | tipranks.com

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec ...

July 7, 2026 | finance.yahoo.com

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

July 7, 2026 | globenewswire.com

Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research

June 11, 2026 | globenewswire.com

Theriva Biologics Faces Quorum Issue Delaying Warrant Vote

June 5, 2026 | tipranks.com

Alliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)

May 7, 2026 | theglobeandmail.com

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

May 5, 2026 | globenewswire.com

Theriva Biologics stock surges on AACR cancer trial data

April 21, 2026 | investing.com

Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial Results

April 21, 2026 | blockonomi.com

Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data

April 20, 2026 | theglobeandmail.com

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual ...

April 19, 2026 | finance.yahoo.com

Therivaâ„¢ Biologics anuncia la prÃ³xima presentaciÃ³n de datos adicionales del ensayo clÃnico VIRAGE de Fase 2b del VCN-01 para el cÃ¡ncer de pÃ¡ncreas metastÃ¡sico en la ReuniÃ³n Anual de la AACR de 2026

April 18, 2026 | globenewswire.com

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

April 17, 2026 | globenewswire.com

Theriva Biologics (TOVX) price target decreased by 37.50% to 2.55

April 10, 2026 | msn.com

Maxim Group upgrades Theriva Biologics (TOVX)

April 1, 2026 | msn.com

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

March 23, 2026 | markets.businessinsider.com

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

March 12, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDI, APRE, MTVA, and TOVX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$0.66 +0.02 (+2.45%)

Closing price 03:59 PM Eastern

Extended Trading

$0.67 +0.01 (+1.50%)

As of 04:10 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Calidi Biotherapeutics NYSEAMERICAN:CLDI

$1.64 +0.01 (+0.61%)

Closing price 04:10 PM Eastern

Extended Trading

$1.65 +0.01 (+0.55%)

As of 07:51 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

MetaVia NASDAQ:MTVA

$1.42 -0.01 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 +0.03 (+1.83%)

As of 07:59 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Theriva Biologics NYSEAMERICAN:TOVX

$0.23 0.00 (-0.43%)

Closing price 04:10 PM Eastern

Extended Trading

$0.23 0.00 (-0.87%)

As of 07:54 PM Eastern

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDI, APRE, MTVA, and TOVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDI, APRE, MTVA, and TOVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDI, APRE, MTVA, and TOVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDI, APRE, MTVA, and TOVX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

Calidi Biotherapeutics NYSEAMERICAN:CLDI

MetaVia NASDAQ:MTVA

Theriva Biologics NYSEAMERICAN:TOVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDI, APRE, MTVA, and TOVX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDI, APRE, MTVA, and TOVX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDI, APRE, MTVA, and TOVX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDI, APRE, MTVA, and TOVX Company Descriptions

Aprea Therapeutics NASDAQ:APRE

Calidi Biotherapeutics NYSEAMERICAN:CLDI

MetaVia NASDAQ:MTVA

Theriva Biologics NYSEAMERICAN:TOVX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools